Moreover, the 36-month beta value for BIAF is 3.15. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BIAF is 9.42M and currently, short sellers hold a 1.23% of that float. On March 13, 2025, BIAF’s average trading volume was 195.98K shares.
BIAF) stock’s latest price update
BioAffinity Technologies Inc (NASDAQ: BIAF)’s stock price has plunge by 15.88relation to previous closing price of 0.35. Nevertheless, the company has seen a 6.84% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-03-06 that SAN ANTONIO–(BUSINESS WIRE)– #BIAF–bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory.
BIAF’s Market Performance
BioAffinity Technologies Inc (BIAF) has experienced a 6.84% rise in stock performance for the past week, with a -49.25% drop in the past month, and a -60.50% drop in the past quarter. The volatility ratio for the week is 21.44%, and the volatility levels for the past 30 days are at 17.45% for BIAF. The simple moving average for the last 20 days is -29.73% for BIAF stock, with a simple moving average of -72.74% for the last 200 days.
BIAF Trading at -42.29% from the 50-Day Moving Average
After a stumble in the market that brought BIAF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.01% of loss for the given period.
Volatility was left at 17.45%, however, over the last 30 days, the volatility rate increased by 21.44%, as shares sank -49.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.76% lower at present.
During the last 5 trading sessions, BIAF rose by +6.84%, which changed the moving average for the period of 200-days by -83.44% in comparison to the 20-day moving average, which settled at $0.5846. In addition, BioAffinity Technologies Inc saw -54.86% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIAF
Current profitability levels for the company are sitting at:
- -0.89 for the present operating margin
- 0.32 for the gross margin
The net margin for BioAffinity Technologies Inc stands at -0.9. The total capital return value is set at -2.06. Equity return is now at value -167.00, with -100.90 for asset returns.
Based on BioAffinity Technologies Inc (BIAF), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -4.19. The debt to equity ratio resting at 0.55. The interest coverage ratio of the stock is -90.02.
Currently, EBITDA for the company is -7.63 million with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 0.79. The receivables turnover for the company is 7.06for trailing twelve months and the total asset turnover is 1.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.02.
Conclusion
To wrap up, the performance of BioAffinity Technologies Inc (BIAF) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
